You are here

Problem

Problem: Unapproved stem-cell therapies are being marketed to people with long COVID

New research has identified 38 direct-to-consumer businesses marketing stem-cell treatments and exosome therapies for COVID-19 infections and, especially, long COVID, despite lacking approval by US Food and Drug Administration and other regulatory body in the United States. Descriptions of the businesses and an analysis of their marketing strategies are published in Stem Cell Reports.

...

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Beyfortus drug to protect infants from RSV is in short supply--CDC warns

 

... The agency told doctors to prioritize getting those doses to infants at the highest risk of severe RSV, including infants younger than 6 months and those with underlying conditions. The CDC also advised doctors to preserve 50 mg doses for infants who weigh less than 11 pounds.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Problem
howdy folks
Page loaded in 0.761 seconds.